Maya Malkin

Maya Malkin, as a Shareholder Partner at Kite Pharma, plays a pivotal role in guiding the company's strategic growth within the rapidly evolving biopharmaceutical landscape. Her current responsibilities extend beyond traditional shareholder duties to encompass active engagement in key projects that drive innovation and operational excellence. Maya is deeply involved in overseeing Kite Pharma’s financial health through meticulous analysis of quarterly and annual reports, ensuring alignment with industry best practices and regulatory standards. Her expertise in market trend analysis and investment analysis skills enables her to evaluate emerging opportunities and mitigate risks effectively, fostering sustainable growth for the company.

In her role, Maya collaborates closely with Kite Pharma’s management team to stay abreast of industry developments, such as advancements in CAR-T cell therapies and immuno-oncology, which are central to the company's pipeline. She participates in strategic decision-making processes, including voting at annual general meetings, and advocates for initiatives that enhance shareholder value. Her background in financial services, combined with her proficiency in industry knowledge and business process optimization, allows her to communicate complex financial and operational insights clearly and effectively.

Moreover, Maya’s experience in transfer pricing, equity research, and direct taxation equips her with a comprehensive understanding of the financial intricacies involved in biopharmaceutical investments. Her commitment to maintaining and growing her investment interests is complemented by her proactive approach to engaging with management and industry stakeholders, ensuring Kite Pharma remains at the forefront of innovative cancer therapies. Through her strategic oversight and industry expertise, Maya Malkin continues to contribute significantly to Kite Pharma’s mission of transforming patient outcomes through cutting-edge biotechnologies.